Bone Cancer Pain: From Mechanism to Model to Therapy

Pain Medicine

Volumn 1, Issue 4, 2000, Pages 303-309

  Honore, Prisca ^a,b   Mantyh, Patrick W ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Astrocyte Hypertrophy; Bone; C fos Protein; Dynorphin; Osteolysis; Osteoprotegerin; Persistent Pain

Indexed keywords

EID: 0001374046     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4637.2000.00047.x     Document Type: Article

References (69)

1. Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991;45:45-8.
2. Coleman RE, Houston S, Purohit OP, Rubens RD, Kandra A, Ford J. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. Eur J Cancer 1998;34: 820-4.
3. Coleman RE. How can we improve the treatment of bone metastases further? Curr Opinion Oncol 1998;10(suppl 1):S7-13.
4. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
5. Rosier R. Bone pain. Am J Hosp Palliat Care 1992; 9:37.
6. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997;80(suppl 8):1668-73.
7. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998;78:157-69.
8. Mercadante S and Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998;24:425-32.
9. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
10. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34.
11. Payne R. Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines. Oncology 1998;12:169-75.
12. Payne R. Mechanisms and management of bone pain. Cancer 1997;80(suppl 8):1608-13.
13. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886-97.
14. Nahin RL, Hylden JLK, Iadarola MJ, Dubner R. Peripheral inflammation is associated with increased dynorphin immunoreactivity in both projection and local circuit neurons in the superficial dorsal horn of the rat lumbar spinal cord. Neurosci Lett 1989;96:247-52.
15. Noguchi K, Kowalski K, Traub R, Solodkin A, Iadarola MJ, Ruda MA. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Mol Brain Res 1991;10:227-33.
16. Laughlin TM, Vanderah TW, Lashbrook J, et al. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 1997;72:253-60.
17. Iadarola MJ, Brady LS, Draisci G, Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 1988;35:313-26.
18. Hylden JL, Noguchi K, Ruda MA. Neonatal capsaicin treatment attenuates spinal Fos activation and dynorphin gene expression following peripheral tissue inflammation and hyperalgesia. J Neurosci 1992; 12:1716-25.
19. Draisci G, Iadarola MJ. Temporal analysis of increases in c-fos, preprodynorphin and preproenkephalin mRNAs in rat spinal cord. Brain Res Mol Brain Res 1989;6:31-7.
20. Draisci G, Kajander KC, Dubner R, Bennett GJ, Iadarola MJ. Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res 1991;560:186-92.
21. Ruda MA, Iadarola MJ, Cohen LV, Young WSI. In situ hybridization histochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model peripheral inflammation and hyperalgesia. Proc Natl Acad Sci USA 1988;85:622-26.
22. Vanderah TW, Laughlin T, Lashbrook JM, et al. Single intrathecal injections of dynorphin A or desTyr-dynorphins produce long-lasting allodynia in rats; Blockade by MK-801 but not naloxone. Pain 1996;68:275-81.
23. Honore P, Buritova J, Fourniezaluski MC, Roques BP, Besson JM. Antinociceptive Effects of Rb101, a Complete Inhibitor of Enkephalin-Catabolizing Enzymes, Are Enhanced By a Cholecystokinin Type B Receptor Antagonist, As Revealed By Noxiously Evoked Spinal C-Fos Expression in Rats. J Pharmacol Exp Ther 1997;281:208-17.
24. Honore P, Buritova J, Chapman V, Besson JM. Up 202-56, an Adenosine Analogue, Selectively Acts Via A(1) Receptors to Significantly Decrease Noxiously-Evoked Spinal C-Fos Protein Expression. Pain 1998;75:281-93.
25. Honore P, Chapman V, Buritova J, Besson JM. To what extent do spinal interactions between an alpha-2 adrenoceptor agonist and a mu opioid agonist influence noxiously evoked c-Fos expression in the rat? A pharmacological study. J Pharmacol Exp Ther 1996;278:393-403.
26. Abbadie C, Honore P, Fournie-Zaluski MC, Roques BP, Besson JM. Effects of opioids and non-opioids on c-Fos-like immunoreactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation. Eur J Pharmacol 1994;258:215-27.
27. Chapman V, Honore P, Buritova J, Besson JM. The contribution of NMDA receptor activation to spinal c-Fos expression in a model of inflammatory pain. Br J Pharmacol 1995;116:1628-34.
28. Chapman V, Honore P, Buritova J, Besson JM. Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat. Neuroscience 1995;67:731-9.
29. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 1987;328:632-4.
30. Munglani R, Hunt SP. Proto-oncogenes: basic concepts and stimulation induced changes in the spinal cord. Prog Brain Res 1995;104:283-98.
31. Doyle CA, Hunt SP. Substance P receptor (neurokinin-1)-expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: a c-Fos study in rat. Neuroscience 1999;89: 17-28.
32. Mantyh PW, Demaster E, Malhotra A, et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 1995;268:1629-32.
33. Mantyh PW, Rogers SD, Honore P, et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor [see comments]. Science 1997;278:275-9.
34. Allen BJ, Li J, Menning PM, et al. Primary afferent fibers that contribute to increased substance P receptor internalization in the spinal cord after injury. J Neurophysiol 1999;81:1379-90.
35. Honore P, Menning PM, Rogers SD, et al. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J Neurosci 1999;19:7670-8.
36. Abbadie C, Trafton J, Liu HT, Mantyh PW, Basbaum AI. Inflammation Increases the Distribution of Dorsal Horn Neurons That Internalize the Neurokinin-1 Receptor in Response to Noxious and Non-Noxious Stimulation. J Neurosci 1997;17:8049-60.
37. Honore P, Chapman V, Buritova J, Besson JM. Reduction of carrageenin oedema and the associated c-Fos expression in the rat lumbar spinal cord by nitric oxide synthase inhibitor. Br J Pharmacol 1995;114:77-84.
38. Jasmin L, Wang H, Tarczy-Hornoch K, Levine JD, Basbaum AI. Noxious stimulus-evoked Fos-like immunoreactivity in spinoparabrachial neurons in lamina I is not affected by morphine. IASP-7th World Congress on Pain; 1993:606.
39. Basbaum AI. Immediate-early genes and pain: What's all the "Fos" about? APSJ 1994;3:49-52.
40. Abbadie C, Besson JM. C-fos expression in rat lumbar spinal cord following peripheral stimulation in adjuvant-induced arthrtis and in normal rats. Brain Res 1993;607:195-204.
41. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumor-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 1998;12:149-68.
42. Mundy GR. Mechanisms of bone metastasis. Cancer 1997;80(suppl 8):1546-56.
43. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997;80(suppl 8):1674-9.
44. Clohisy DR, Ogilvie CM, Carpenter RJ, Ramnaraine ML. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 1996;14:2-6.
45. Clohisy DR, Palkert D, Ramnaraine ML, Pekurovsky I, Oursler MJ. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. J Orthop Res 1996;14:396-402.
46. Clohisy DR, Ogilvie CM, Ramnaraine ML. Tumor osteolysis in osteopetrotic mice. J Orthop Res 1995; 13:892-7.
47. Hokfelt T, Zhang X, Wiesenfeld-Hallin Z. Messenger plasticity in primary sensory neurons following axotomy and its functional implications [see comments]. Trends Neurosci 1994;17:22-30.
48. Fields, HL. Pain modulation: opiates and chronic pain. NIDA Res Monogr 1989;95:92-101.
49. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000;98:585-98.
50. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neuro-chemical reorganization of the spinal cord. Nat Med 2000;6:521-8.
51. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
52. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin - a Novel Secreted Protein Involved in the Regulation of Bone Density. Cell 1997;892: 309-19.
53. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;932:165-76.
54. Kostenuik PJ, Morony S, Capparelli C, Lacey DL, Dunstan CR. Comparison of the inhibitory effects of osteoprotegerin and of APD on PTHrP-mediated hypercalcemia and bone remodeling. J Bone Miner Res 1999;14:S166.
55. Delaisse J-M, Vaes G. Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In: Rifkin BR, Gay CV, eds. Biology and Physiology of the Osteoclast. Ann Arbor: CRC; 1992:289-314.
56. Olson TH, Riedl MS, Vulchanova L, Ortiz-Gonzalez XR, Elde R. An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. Neuroreport 1998;9:1109-13.
57. Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour Necrosis Factor-Alpha Induces Ectopic Activity in Nociceptive Primary Afferent Fibres. Neuroscience 1997;81:255-62.
58. Tonussi CR, Ferreira SH. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain. 1999;82: 81-7.
59. O'Connell JX, Nanthakumar SS, Nielsen GP, Rosenberg AE. Osteoid osteoma: the uniquely innervated bone tumor. Modern Pathol 1998;11: 175-80.
60. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P-and CGRP-immunoreactive nerves in bone. Peptides 1988;9:165-71.
61. Hill EL, Elde R. Distribution of CGRP-, VIP-, DβH-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res 1991; 264:469-80.
62. Tabarowski Z, Gibson-Berry K, Felten SY. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochem 1996;98:453-7.
63. Goni MH, Tolis G. Hypercalcemia of cancer: an update. Anticancer Res 1993;13:1155-60.
64. Suzuki K, Yamada S. Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor alpha, interleukin-1 alpha and interleukin-6. Bone Miner 1994;273:219-33.
65. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of Cy-tokine-Induced Hyperalgesia. Brain Res 1994;654: 15-26.
66. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 1995;115:1265-75.
67. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 1997; 121:417-24.
68. Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 1998;9:2279-83.
69. Hans G, Davar G. Recent advances in the pharmacology of nerve-injury pain. Neurol Clin 1998;16: 951-66.